In Q1 2024, Adalvo successfully submitted a total of 329 Marketing Authorisation (MA) applications, spanning 55 countries and representing collaborative efforts with 31 strategic partners.
On top of this, Adalvo achieved 361 MA approvals, obtained across 35 countries. With the support of 37 esteemed partners, Adalvo continues to introduce high-quality differentiated medications to markets worldwide.
Adalvo extends sincere appreciation to all stakeholders for their support and looks forward to building upon this momentum.
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner up now